{"id":"eslicarbazepine-acetate-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Somnolence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by reducing the frequency and severity of seizures in patients with epilepsy. This is achieved by inhibiting the activity of voltage-gated sodium channels, which are responsible for the rapid depolarization of neurons. By stabilizing neuronal membranes, eslicarbazepine acetate reduces the excitability of neurons and prevents the spread of seizure activity.","oneSentence":"Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes neuronal membranes and suppresses post-tetanic potentiation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:59:50.410Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures"}]},"trialDetails":[{"nctId":"NCT06597084","phase":"PHASE2","title":"Anti-epileptogenic Effects of Eslicarbazepine Acetate","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2019-05-29","conditions":"Post Stroke Epilepsy","enrollment":129},{"nctId":"NCT01879345","phase":"PHASE1","title":"A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-10","conditions":"Epilepsy","enrollment":18},{"nctId":"NCT02281591","phase":"PHASE1","title":"Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-06","conditions":"Epilepsy","enrollment":32},{"nctId":"NCT02172742","phase":"PHASE1","title":"The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2002-05","conditions":"Epilepsy","enrollment":13},{"nctId":"NCT00957047","phase":"PHASE3","title":"Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-07","conditions":"Partial Epilepsy","enrollment":395},{"nctId":"NCT00957684","phase":"PHASE3","title":"Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-07","conditions":"Refractory Partial Epilepsy","enrollment":402},{"nctId":"NCT00988429","phase":"PHASE3","title":"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2008-12-02","conditions":"Partial Epilepsy","enrollment":653},{"nctId":"NCT03116828","phase":"PHASE4","title":"A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2017-07-07","conditions":"Epilepsy With Partial On-set Seizures","enrollment":102},{"nctId":"NCT04095182","phase":"PHASE1","title":"Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult","status":"COMPLETED","sponsor":"Whanin Pharmaceutical Company","startDate":"2019-08-22","conditions":"Partial-onset Seizures With or Without Secondary Generalisation","enrollment":50},{"nctId":"NCT02484001","phase":"PHASE3","title":"Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2016-03-01","conditions":"Epilepsy","enrollment":206},{"nctId":"NCT03108729","phase":"PHASE3","title":"A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug","status":"WITHDRAWN","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2017-07-06","conditions":"Epilepsy","enrollment":""},{"nctId":"NCT02170064","phase":"PHASE2","title":"Pharmacokinetics, Efficacy and Tolerability of BIA 2-093","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2005-06","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT02170077","phase":"PHASE2","title":"A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2002-04","conditions":"Epilepsy","enrollment":144},{"nctId":"NCT01422720","phase":"PHASE3","title":"Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2010-04","conditions":"Epilepsy","enrollment":72},{"nctId":"NCT03116321","phase":"PHASE1","title":"Bioequivalence of Two Different Sources of Eslicarbazepine Acetate","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2016-12-03","conditions":"Epilepsy","enrollment":24},{"nctId":"NCT01532726","phase":"","title":"Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2012-03","conditions":"Epilepsy","enrollment":56},{"nctId":"NCT02171195","phase":"PHASE1","title":"A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2000-07","conditions":"Epilepsy","enrollment":64},{"nctId":"NCT00980746","phase":"PHASE2","title":"Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-11","conditions":"Painful Diabetic Neuropathy","enrollment":557},{"nctId":"NCT02777671","phase":"PHASE1","title":"Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-10","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT01830400","phase":"","title":"A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-04","conditions":"Partial Onset Seizures","enrollment":254},{"nctId":"NCT02284880","phase":"PHASE1","title":"Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2010-10","conditions":"Epilepsy","enrollment":40},{"nctId":"NCT01678976","phase":"PHASE1","title":"Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2002-03","conditions":"Epilepsy","enrollment":13},{"nctId":"NCT02288312","phase":"PHASE1","title":"Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-05","conditions":"Epilepsy","enrollment":18},{"nctId":"NCT02171234","phase":"PHASE1","title":"A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2001-02","conditions":"Epilepsy","enrollment":32},{"nctId":"NCT02279667","phase":"PHASE1","title":"Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-02","conditions":"Epilepsy","enrollment":18},{"nctId":"NCT01879332","phase":"PHASE1","title":"A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-12","conditions":"Epilepsy","enrollment":16},{"nctId":"NCT02283840","phase":"PHASE1","title":"Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-05","conditions":"Epilepsy","enrollment":60},{"nctId":"NCT00981227","phase":"PHASE2","title":"Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-11","conditions":"Postherpetic Neuralgia","enrollment":567},{"nctId":"NCT01527513","phase":"PHASE2","title":"Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2010-08","conditions":"Partial Epilepsy","enrollment":123},{"nctId":"NCT01129960","phase":"PHASE3","title":"Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain","status":"TERMINATED","sponsor":"Bial - Portela C S.A.","startDate":"2010-11","conditions":"Painful Diabetic Neuropathy","enrollment":332},{"nctId":"NCT00957372","phase":"PHASE3","title":"Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-12","conditions":"Partial Epilepsy","enrollment":253},{"nctId":"NCT01124097","phase":"PHASE3","title":"Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia","status":"TERMINATED","sponsor":"Bial - Portela C S.A.","startDate":"2010-09","conditions":"Post Herpetic Neuralgia","enrollment":240},{"nctId":"NCT01824602","phase":"PHASE2","title":"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder","status":"TERMINATED","sponsor":"Bial - Portela C S.A.","startDate":"2006-02","conditions":"BIPOLAR I DISORDER","enrollment":38},{"nctId":"NCT01822678","phase":"PHASE2","title":"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2005-12","conditions":"Bipolar I Disorder","enrollment":161},{"nctId":"NCT01825837","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-03","conditions":"Bipolar I Disorder","enrollment":104},{"nctId":"NCT01878578","phase":"PHASE1","title":"The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients","status":"TERMINATED","sponsor":"Bial - Portela C S.A.","startDate":"2002-11","conditions":"Epilepsy","enrollment":4},{"nctId":"NCT01820585","phase":"PHASE2","title":"Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-04","conditions":"Fibromyalgia","enrollment":528},{"nctId":"NCT01820559","phase":"PHASE2","title":"Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-04","conditions":"Migraine","enrollment":452}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ESL"],"phase":"phase_2","status":"active","brandName":"Eslicarbazepine Acetate tablets","genericName":"Eslicarbazepine Acetate tablets","companyName":"Eisai Inc.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes neuronal membranes and suppresses post-tetanic potentiation. Used for Partial-onset seizures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}